Psychedelic People

Emmanuelle Schindler

Emmanuelle Schindler is a board-certified Neurologist at Yale School of Medicine in New Haven, with a PhD in Neuroscience. Her research focus on enhancing the understanding of and improving the lives of patients with cluster headache.

Mason Freeman
Director, Translational Research Center, Massachusetts General Hospital; Physician, Lipid Metabolism, Massachusetts General Hospital; Physician Investigator, Lipid Metabolism, Mass General Research Institute; Professor of Medicine, Harvard Medical School.
Diego Pizzagalli
Diego Pizzagalli is Porfessor of Psychiatry at Harvard Medical School and is an internationally known expert on the neurobiology of depression and has made major contributions toward the identification of biomarkers of depression and treatment response.
Michael Bloch
Associate Professor in the Child Study Center; Co-Director and Co-Founder of the Pediatric Depression Clinic, Child Study Center; Co-Director of the T32 Postdoctoral Research Fellowship in Childhood Neuropsychiatric Disorders, Child Study Center; Associate Director, Albert J. Solnit Integrated Training Program, Child Study Center; Co-Director of the Tic and OCD Program, Child Study Center
Johan Lundberg
Johan Lundberg currently works at the Department of Clinical Neuroscience, Karolinska Institutet where he is a group leader and associate professor in psychiatry.
Benjamin Kelmendi
Benjamin Kelmendi is a board-certified psychiatrist and is an Assistant Professor in the Department of Psychiatry at the Yale University School of Medicine and is also a co-founder of the Yale Psychedelic Science Group.
Otto Simonsson
Otto Simonsson is a Postdoctoral Research Fellow at the Karolinska Institute where he conducts research on meditation and psychedelics. Otto held a similar position at The Centre for Healthy Minds at the University of Wisconsin-Madison.
Dong-Xin Wang
Dong-Xin Wang is a Professor and Chairman of the Department of Anesthesiology and Critical Care Medicine at Peking University First Hospital.
José Carlos Bouso
José Carlos Bouso is a Clinical Psychologist with a PhD in Pharmacology and is the current Scientific Director at ICEERS.
Declan McLoughlin
Declan McLoughlin is a Research Professor of Psychiatry at the Trinity Institute of Neurosciences (TCIN) in Trinity College Dublin.
Rafael dos Santos
Rafael dos Santos is a postdoctoral fellow at the Graduate Program in Mental Health at the Faculty of Medicine of Ribeirão Preto (FMRP-USP), where he also works as an accredited advisor.
Anders Fink-Jensen
Anders Fink-Jensen is a Professor of Clinical Psychiatry at the University of Copenhagen.
Deborah Mash
Deborah Mash is a professor Neurology and Molecular and Cellular Pharmacology at the University of Miami School of Medicine. She is also the Chief Executive Officer and founder of clinical stage pharmaceutical development company DemeRx. Her research is focused on the potential use of ibogaine for opioid and other substance abuse disorders.
Maria Galusko-Wegielink
Research Institute
Maria Gałuszko-Węgielnik is a psychiatrist associated with the Medical University of Gdansk. Her psychedelic work is currently investigating the effect of ketamine on (treatment-resistant) depression.
Mohini Ranganathan
Mohini Ranganathan is an Associate Professor of Psychiatry at Yale School of Medicine and is affiliated with Veterans Affairs Connecticut Healthcare System-West Haven.
Franklin Schneier
Franklin Schneier is a Special Lecturer at Columbia University College of Physicians and Surgeons and Research Psychiatrist in the Anxiety Disorders Clinic at New York State Psychiatric Institute.
Dan Iosifescu
Research Institute
Dan Iosifescu is an Associate Professor of Psychiatry at NYU School of Medicine and Director of Research at the Nathan S. Kline Institute for Psychiatric Research.
Amelia Adcock
Amelia Adcock is an Associate Professor in the Department of Neurology at West Virginia University.
Joshua Rosenblat
Joshua Rosenblat is a psychiatrist and clinician-researcher at the Mood Disorders Psychopharmacology Unit at the University of Toronto. He is also the Medical Director of the Canadian Rapid Treatment Centre of Excellence (CRCTE), Chief Medical & Scientific Officer of Braxia Scientific and co-founder of 1907 Research.
Pierre Blier
Pierre Blier is a Professor at the University of Ottawa, Department of Psychiatry and Cellular/Molecular Medicines and the recipient of the Endowed Chair in Mood Disorders Research at the University of Ottawa Institute of Mental Health Research (IMHR).
Madeline Li
Madeline Li is an Associate Professor in the Department of Psychiatry, University Health Network and a clinician-scientist in the Department of Psychosocial Oncology and Palliative Care a the University of Toronto.
Anne Wagner
Anne Wagner is the Founder of Remedy, a clinical psychologist and treatment development researcher based in Toronto.
James Downar
James Downar is a Critical Care and Palliative Care Physician at the University Health Network and Sinai Health System in Toronto, and an Associate Professor in the Department of Medicine at the University of Toronto.
Mark Niciu
Mark Niciu is an Assistant Professor of Psychiatry at the University of Iowa. Mark and his team are interested in the therapeutic effects of ketamine.
Eric Lenze
Eric Lenze is the Wallace & Lucille Renard Professor of Psychiatry and the Director of the Healthy Mind Lab at Washington University School of Medicine. As part of his research, Lenze has explored the therapeutic effects of ketamine in older adults.
Dulce Martinez
Dulce Maria Rascon Martinez is an Associate Professor in the Department of Anaesthesiology at the Instituto Mexicano del Seguro Social
Jennifer Jones
Jennifer Jones is a board-certified psychiatrist and clinical researcher a the Medical University of South Carolina with comprehensive training in Ketamine-Assisted Psychotherapy.
Peter Hendricks
Peter Hendricks is a Professor in the Department of Health Behaviour at the University of Alabama. Hendricks's area of expertise lies in substance abuse treatment and prevention.
Sanjay Mathew
Sanjay is a Professor of Psychiatry and Behavioral Sciences and the Director of the Mood and Anxiety Disorders Program at Baylor College of Medicine. He is currently exploring the use of ketamine in treating mood disorders.
Steven Levine
Steve was formerly the founder and Chief Medical Officer of Actify Neurotherapies, administering over 60,000 ketamine infusions. He is now VP of Patient Access at COMPASS Pathways.

Find People

Need to know who is leading a psychedelic company, or what research has been published by a specific researcher? Then look no further with our database of psychedelic people.

The psychedelic people database is currently in development and will near completion later in 2022. For suggestions on information to track, you can always contact us.

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account